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Leishmaniosis is a vector-borne disease caused by protozoans of the genus Leishmania, which 
are transmitted to vertebrates, including cats, through the bites of female phlebotomine sandflies. 
An increasing number of epidemiological and experimental studies concerning Leishmania 
infection in cats, as well as case reports of clinical leishmaniosis in these felids, have been 
published in recent years. In the present study, a comprehensive review was made by sourcing 
the National Library of Medicine resources to provide updated data on epidemiology, 
immunopathogenesis, diagnosis, treatment, and prevention of feline leishmaniosis. Cats were 
found infected with Leishmania parasites worldwide, and feline leishmaniosis appears as an 
emergent disease mostly reported in countries surrounding the Mediterranean Sea and Brazil. 
Cats with impaired immunocompetence seem to have a higher risk to develop clinical disease. 
The main clinical and clinicopathological findings are dermatological lesions and 
hypergammaglobulinemia, respectively. Diagnosis of feline leishmaniosis remains a challenge 
for veterinarians, in part, due to the lack of diagnosis support systems. For this reason, a 
diagnostic algorithm for clinical decision support is proposed for the first time here. No 
evidence-based treatment protocols are currently available, and these remain empirically based.  
Control measures are limited and scarce. Thus, a set of prevention guidelines are herein 
suggested. 














Leishmaniosis is a disease that affects humans and both domestic and wild animals 
worldwide and is caused by protozoans of the genus Leishmania.  The infection typically occurs 
through the bites of female phlebotomine sand flies of the genera Phlebotomus in the Old World 
and Lutzomyia in the New World (WHO, 2010).  
In contrast to dogs, cats have been considered for several years as accidental hosts 
resistant to leishmaniosis. Nevertheless, this felid now appears as a relevant piece within the 
ecological system in which Leishmania parasites are maintained indefinitely (Asfaram et al., 
2019). Feline Leishmania infection has frequently been reported in endemic areas of South 
America, Southern Europe and Western Asia, and the number of reported cases of feline 
leishmaniosis has been increasing in recent years (Pereira et al., 2019b; Baneth et al., 2020; da 
Costa-Val et al., 2020; Fernandez-Gallego et al., 2020). 
The present review aimed to provide updated information concerning the epidemiology 
of Leishmania infection in cats and clinical management of feline leishmaniosis (FeL) with 
emphasis on immunopathogenesis, diagnosis, treatment, prognosis, and prevention, as well as 
the development of an algorithm to assist diagnosis and delineate strategic guidelines to prevent 
feline infection. 
 
2. Search strategy, eligibility, and review  
 
A comprehensive literature search was performed on 10 March 2021 by sourcing 
National Library of Medicine (NLM) resources through PubMed 
(https://pubmed.ncbi.nlm.nih.gov/) using the following Boolean string: (“leishmania” [MeSH 
Terms] OR “leishmania”[All Fields] OR “leishmanias” [All Fields] OR “leishmaniae” [All 
Fields] OR (“leishmaniasis” [MeSH Terms] OR “leishmaniasis” [All Fields] OR “leishmaniosis” 
[All Fields] OR “leishmaniases” [All Fields])) AND (“cat” [All Fields] OR (“felis” [MeSH 
Terms] OR “felis” [All Fields]) OR (“felidae” [MeSH Terms] OR “felidae” [All Fields] OR 
“felid” [All Fields] OR “felids” [All Fields]) OR (“cats” [MeSH Terms] OR “cats” [All Fields] 
OR “felines” [All Fields] OR “felidae” [MeSH Terms] OR “felidae” [All Fields] OR “feline” 
[All Fields])). Search results were saved as a comma-separated value (CSV) file, subsequently 
imported into Microsoft® Excel®. Study eligibility was manually assessed by two independent 
investigators in a blinded manner. Only available original research articles concerning 
Leishmania infection in cats were retained, including those published in languages other than 








Leishmania spp. in felids belonging to the genus Felis), the present review refers exclusively to 
infection of domestic cats (Felis catus) by L. donovani (sensu lato). Although this complex is 
formally comprised of L. donovani (sensu stricto), L. chagasi and L. infantum, for the remainder 
of this review, L. infantum will be used to refer strictly to feline infection by L. donovani (s.l.). 
 
3. Aetiology, distribution, and risk factors 
 
To date, six species belonging to the subgenus Leishmania and one to the subgenus 
Viannia have been identified in domestic cats (F. catus) through DNA or isoenzyme-based 
typing methods (Fig. 2):  
(i) L. (L.) amazonensis in Brazil (De Souza et al., 2005; Carneiro et al., 2020);  
(ii) L. (L.) infantum in Brazil (Schubach et al., 2004; De Souza et al., 2005; da Silva et al., 
2008; Vides et al., 2011; Sobrinho et al., 2012; de Morais et al., 2013; Benassi et al., 2017; 
Metzdorf et al., 2017; Marcondes et al., 2018; Rocha et al., 2019; Berenguer et al., 2020; da 
Costa-Val et al., 2020; ), southern Europe (Ayllón et al., 2008, 2012; Maia et al., 2008; Tabar et 
al., 2008; Maia et al., 2010; Millán et al., 2011; Chatzis et al., 2014a; Maia et al., 2014, 2015b; 
Persichetti et al., 2016, 2018; Attipa et al., 2017a; Diakou et al., 2017; Otranto et al., 2017; 
Colella et al., 2019; Pereira et al., 2019c, 2020; Ebani et al., 2020), western Europe (Ozon et al., 
1998; Pratlong et al., 2004; Pocholle et al., 2012; Richter et al., 2014) and western Asia (Hatam 
et al., 2010; Dincer et al., 2015; Akhtardanesh et al., 2017; Attipa et al., 2017b; Mohebali et al., 
2017; Karakuş et al., 2019; Asgari et al., 2020; Baneth et al., 2020);  
(iii) L. (L.) major in Portugal (Pereira et al., 2020) and Turkey (Paşa et al., 2015);  
(iv) L. (L.) mexicana in the USA (Craig et al., 1986; Trainor et al., 2010; Minard et al., 
2017) and Venezuela (Rivas et al., 2018);  
(v) L. (L.) tropica in western Asia (Paşa et al., 2015; Can et al., 2016; Akhtardanesh et al., 
2017); 
(vi) L. (L.) venezuelensis in Venezuela (Bonfante-Garrido et al., 1991);  
(vii) and L. (V.) braziliensis in Brazil (Schubach et al., 2004; da Costa-Val et al., 2020) 
and French Guiana (Rougeron et al., 2011).  
Besides, DNA of L. infantum and putative L. major/L. donovani (s.l.) hybrid parasites 
were detected in wild cats (Felis silvestris) in Spain (Del Río et al., 2014) and in a domestic cat 
in mainland Portugal (Pereira et al., 2020), respectively. 
The proportion of cats infected with or exposed to Leishmania has been assessed in 
several epidemiological studies through parasitological, serological, or molecular methods 








influenced by local endemicity, sampling bias and heterogeneity/performance of diagnostic 
methodologies (manly cut-off, target gene and sample used for testing).  
Specific antibodies or Leishmania DNA have been mostly detected in domestic cats 
living in endemic areas of South America, the Mediterranean Region and western Asia. Some 
studies also suggest that wild cats from Spain (Del Río et al., 2014; Risueño et al., 2018) and 
sand cats (Felis margarita) from Saudi Arabia (Morsy et al., 1999) are frequently exposed to 
Leishmania infection.  
In non-endemic countries, as seen in dogs, feline Leishmania infection has been 
particularly associated with cats travelling to or rehomed from southern Europe and Brazil 
(Rüfenacht et al., 2005; Richter et al., 2014; Maia & Cardoso, 2015; Schäfer et al., 2021). Also, 
antibodies to Leishmania were detected in three domestic cats living in the UK, but in all cases, 
the travel and clinical history were unknown (Persichetti et al., 2017). 
Although blood transfusion is regarded as a probable non-vector-borne transmission 
pathway of Leishmania in cats, no feline infection cases by this parasite (screened by PCR) were 
identified among eligible blood donors (Marenzoni et al., 2018; Mesa-Sanchez et al., 2020). 
Several factors have been highlighted as possibly associated with Leishmania infection in 
cats based on univariate analysis, including old age (Akhtardanesh et al., 2017; Junsiri et al., 
2017; Morganti et al., 2019; Asgari et al., 2020), male sex (Cardoso et al., 2010; Sobrinho et al., 
2012; Montoya et al., 2018a; Asgari et al., 2020; Latrofa et al., 2020), non-neutered status 
(Otranto et al., 2017; Latrofa et al., 2020), presence of clinical or clinicopathological 
abnormalities (such as crusting skin lesions, leukopaenia, increase in alanine aminotransferase 
(ALT) levels, lymphadenomegaly, lymphocytosis and neutrophilia) (Ayllón et al., 2008; Sherry 
et al., 2011; Sobrinho et al., 2012; Spada et al., 2013; Akhtardanesh et al., 2017; Otranto et al., 
2017; Latrofa et al., 2020),  concomitant infections (such as feline coronavirus (FCoV), feline 
immunodeficiency virus (FIV), feline leukaemia virus and Toxoplasma gondii) (Sherry et al., 
2011; Sobrinho et al., 2012; Spada et al., 2013, 2016; Montoya et al., 2018a), geographical 
area/local environment (such as altitude and rural areas) (Nasereddin et al., 2008; Cardoso et al., 
2010; Asgari et al., 2020), lifestyle (such as access to the outdoors) (Rocha et al., 2019) and 
cohabitation with dogs (Rocha et al., 2019; Morelli et al., 2020). Epidemiological studies using 
logistic regression models (a powerful analytic research tool that avoids confounding effects) 
have evidenced that adult cats (Iatta et al., 2019; Akhtardanesh et al., 2020), males (Iatta et al., 
2019; Akhtardanesh et al., 2020), non-neutered (Iatta et al., 2019), or with concomitant 
infections by FeLV (Martín-Sánchez et al., 2007; Sherry et al., 2011; Spada et al., 2013; 








Mycoplasma turicensis” or Hepatozoon spp. (Attipa et al., 2017b) have an increased risk for 
Leishmania infection. 
 
4. Immunopathogenesis  
 
In dogs, several studies have provided evidence demonstrating that the course of L. 
infantum infection is directly linked to the immune response. Development of progressive 
disease in susceptible dogs is typically characterised by high antibody levels and an impaired 
ability to mount a strong and effective cell-mediated response characterised by the expression of 
interferon-gamma (IFN-γ), tumour necrosis factor-alpha (TNF-α), and interleukin (IL)-2 
(reviewed by Maia & Campino, 2018). However, very limited data are available on the 
pathogenesis of leishmaniosis in cats. Experimental studies involving intravenous/intraperitoneal 
inoculation of axenic promastigotes suggest that cats are hypothetically less susceptible to 
developing disease by L. infantum when compared to dogs, despite also presenting a long-lasting 
parasitaemia (Kirkpatrick et al., 1984; Akhtardanesh et al., 2018). Recently, Priolo et al. (2019) 
demonstrated that cats naturally exposed to L. infantum infection produce IFN-γ following ex 
vivo blood stimulation with parasite antigens, as reported in dogs (Solano-Gallego et al., 2016). 
This finding is important to highlight that Leishmania parasites can elicit a protective cell-
mediated immune response in cats. The only study assessing the role of the complement system 
in feline L. infantum infection showed that, contrary to humans and dogs, cat’s proteins are 
consumed by parasites in the lectin pathway, which hypothetically may justify their low 
predisposition to develop clinical disease (Tirado et al., 2021). 
 
5. Clinical presentation and clinicopathological findings 
 
Feline leishmaniosis caused by L. infantum is mostly reported in adult (median age: 7 
years; range: 2–21 years) domestic short-hair cats living in or travelling to endemic countries of 
southern Europe and Brazil. The disease has a chronic course and may be manifested by a 
plethora of clinical signs and/or clinicopathological abnormalities, which are summarised in 
Table 3 and Table 4, respectively. About one-third of cats with leishmaniosis showed 
concomitant infections/diseases including FIV (Hervás et al., 2001; Poli et al., 2002; Pennisi et 
al., 2004; Grevot et al., 2005; Pocholle et al., 2012; Pimenta et al., 2015; Fernandez-Gallego et 
al., 2020), FeLV (Poli et al., 2002; Grevot et al., 2005; Pereira et al., 2019c), FCoV (Pennisi et 
al., 2004; Savani et al., 2004), T. gondii (Pennisi et al., 2004), Bartonella henselae (Pennisi et al., 








neoplasia (Grevot et al., 2005; Pocholle et al., 2012; Maia et al., 2015b) and/or were under 
immunosuppressive therapies at the time of diagnosis (Fernandez-Gallego et al., 2020). 
Dermatological disorders were found in about 75% of reported clinical cases. Although 
uncommon, they may occur in the apparent absence of other obvious signs of disease 
(Fernandez-Gallego et al., 2020). Nodular dermatitis seems to be the main cutaneous lesion 
associated with FeL and is typically found on the eyelids (Hervás et al., 2001; Richter et al., 
2014; Pimenta et al., 2015; Leal et al., 2018; Pereira et al., 2019c; Fernandez-Gallego et al., 
2020; Silva et al., 2020). Erosive/ulcerative dermatitis is another clinical finding suggestive of 
FeL and has been identified on the head (Hervás et al., 2001; Grevot et al., 2005; Coelho et al., 
2010; Pocholle et al., 2012; Maia et al., 2015b; Basso et al., 2016; Brianti et al., 2019; Headley et 
al., 2019; Fernandez-Gallego et al., 2020), extremities (Rüfenacht et al., 2005; Coelho et al., 
2010; Basso et al., 2016; Fernandez-Gallego et al., 2020; Silva et al., 2020), trunk (Pocholle et 
al., 2012; Fernandez-Gallego et al., 2020), and over bony prominences (Hervás et al., 1999). 
Although less frequent, some cats with clinical leishmaniosis showed onychogryphosis (da Silva 
et al., 2010; Headley et al., 2019), a rather specific sign of canine leishmaniosis (CanL) (Maia & 
Campino, 2018). Generalised or focal lymphadenopathy appears as a common finding in FeL 
(Hervás et al., 1999, 2001; Poli et al., 2002; Savani et al., 2004; Pennisi et al., 2004; Maroli et 
al., 2007; da Silva et al., 2010; Brianti et al., 2019; Fernandez-Gallego et al., 2020; Silva et al., 
2020) as well as non-specific signs including lethargy/depression (Poli et al., 2002; Pennisi et al., 
2004; Leiva et al., 2005; Rüfenacht et al., 2005; Marcos et al., 2009; Pocholle et al., 2012; 
Richter et al., 2014; Fernandez-Gallego et al., 2020), anorexia/inappetence (Pennisi et al., 2004; 
Rüfenacht et al., 2005; Marcos et al., 2009; da Silva et al., 2010; Fernandez-Gallego et al., 2020), 
and weight loss (Ozon et al., 1998; Hervás et al., 1999; Pennisi et al., 2004; Savani et al., 2004; 
da Silva et al., 2010; Fernandez-Gallego et al., 2020; Silva et al., 2020). 
Approximately one-fourth of cats with clinical leishmaniosis showed uveitis (Hervás et 
al., 2001; Pennisi et al., 2004; Verneuil, 2013; Richter et al., 2014; Pimenta et al., 2015; Leal et 
al., 2018; Pereira et al., 2019c; Fernandez-Gallego et al., 2020); stomatitis (Hervás et al., 2001; 
Leiva et al., 2005; Maroli et al., 2007; Verneuil, 2013; Maia et al., 2015b; Migliazzo et al., 2015; 
Fernandez-Gallego et al., 2020) and/or cardiorespiratory signs such as dyspnoea/tachypnoea, 
pallor, abnormal respiratory sounds, nasal discharge and sneezing (Hervás et al., 2001; Pennisi et 
al., 2004; Marcos et al., 2009; da Silva et al., 2010; Richter et al., 2014; Migliazzo et al., 2015; 
Maia et al., 2015b; Basso et al., 2016; Leal et al., 2018; Headley et al., 2019; Altuzarra et al., 
2020; Silva et al., 2020). Musculoskeletal (i.e. muscle atrophy; da Silva et al., 2010), 
neurological (i.e. ataxia; Fernandez-Gallego et al., 2020), and urogenital (i.e. vaginal bleeding; 








secondary to concomitant diseases (Maia et al., 2015b; Fernandez-Gallego et al., 2020). Other 
clinical manifestations rarely found and which may represent a further diagnostic challenge to 
veterinarians include: depigmentation (Rüfenacht et al., 2005; Pocholle et al., 2012), cutaneous 
bloody cyst (Pennisi et al., 2004), pruritus (Rüfenacht et al., 2005; Pocholle et al., 2012), footpad 
hyperkeratosis (Fernandez-Gallego et al., 2020), hepatomegaly (Pennisi et al., 2004; Leiva et al., 
2005), splenomegaly (Poli et al., 2002; Leal et al., 2018), bruising (Maia et al., 2015b), mastitis 
(Pereira et al., 2019c), chorioretinitis (Pennisi et al., 2004; Fernandez-Gallego et al., 2020), 
corneal opacification (Hervás et al., 2001; Pimenta et al., 2015), glaucoma (Leiva et al., 2005; 
Richter et al., 2014), blepharitis (Brianti et al., 2019), chemosis (Fernandez-Gallego et al., 2020), 
ocular masses (Hervás et al., 2001), glossitis (Fernandez-Gallego et al., 2020), jaundice (Hervás 
et al., 1999; Fernandez-Gallego et al., 2020), abdominal distension (Leiva et al., 2005), and 
vomiting/diarrhoea (Hervás et al., 1999; Fernandez-Gallego et al., 2020). 
Most consistent laboratory abnormalities found in FeL cases include anaemia (generally 
of the normochromic, normocytic type) (Hervás et al., 1999; Pennisi et al., 2004; Marcos et al., 
2009; Richter et al., 2014; Pimenta et al., 2015; Pereira et al., 2019c; Fernandez-Gallego et al., 
2020) and hyperproteinaemia with hypergammaglobulinaemia (Ozon et al., 1998; Hervás et al., 
1999; Poli et al., 2002; Pennisi et al., 2004; Leiva et al., 2005; Marcos et al., 2009; Richter et al., 
2014; Basso et al., 2016; Leal et al., 2018; Brianti et al., 2019; Pereira et al., 2019c; Altuzarra et 
al., 2020; Fernandez-Gallego et al., 2020). The latter was detected in more than 80% of sick cats 
and should be investigated as a possible biomarker of FeL. Leukocytosis (Ozon et al., 1998; da 
Silva et al., 2010; Fernandez-Gallego et al., 2020) and leukopaenia (Pennisi et al., 2004; 
Rüfenacht et al., 2005; Richter et al., 2014) are inconsistent findings, whereas thrombocytopenia 
(Pennisi et al., 2004; Marcos et al., 2009; Richter et al., 2014; Pimenta et al., 2015; Basso et al., 
2016; Pereira et al., 2019c) and azotaemia (Pennisi et al., 2004; Leiva et al., 2005; Marcos et al., 
2009; da Silva et al., 2010; Leal et al., 2018; Fernandez-Gallego et al., 2020) have been 
frequently reported. About a quarter of the sick cats presented proteinuria (Marcos et al., 2009; 
Leal et al., 2018; Fernandez-Gallego et al., 2020), suggesting a possible association between FeL 
and kidney disease as described in dogs. Recently, Chatzis et al. (2020) observed that cats 
infected with Leishmania parasites had higher concentrations of inorganic phosphorus than non-
infected cats, reinforcing this assumption. Mild increases of liver enzyme activities are also 












Clinical presentation combined with epidemiological context may lead to suspicion of 
FeL, but for a definitive diagnosis, Leishmania-specific laboratory tests are required (Table 5). 
These include direct tests (cytology, histology, immunohistochemistry, culture, and PCR), 
demonstrating the presence of the parasite or its components, and indirect tests (serology) 
assessing the host’s response to the parasite infection.  
Cytology is strongly advised in cats presenting erosive/ulcerative skin disease, nodular 
lesions and/or lymphadenomegaly (Hervás et al., 1999; Poli et al., 2002; Savani et al., 2004; 
Coelho et al., 2010; Richter et al., 2014; Maia et al., 2015b; Pimenta et al., 2015; Basso et al., 
2016; Attipa et al., 2017a; Leal et al., 2018; Brianti et al., 2019; Headley et al., 2019; Pereira et 
al., 2019c; Silva et al., 2020). Material for diagnosis can be obtained by fine-needle biopsy (with 
or without aspiration), scraping or imprinting. The presence of Leishmania parasites has been 
demonstrated in cytological examinations of feline nodular lesions (Poli et al., 2002; Savani et 
al., 2004; Richter et al., 2014; Pimenta et al., 2015; Basso et al., 2016; Attipa et al., 2017a; Leal 
et al., 2018; Brianti et al., 2019; Pereira et al., 2019c; Fernandez-Gallego et al., 2020; Silva et al., 
2020), erosive/ulcerative lesions (Maia et al., 2015b; Headley et al., 2019; Fernandez-Gallego et 
al., 2020; Silva et al., 2020), whole-blood (Marcos et al., 2009; Metzdorf et al., 2017), buffy 
coat/leucoconcentrate (Martín-Sánchez et al., 2007, Marcos et al., 2009), lymph nodes (Hervás et 
al., 1999; Poli et al., 2002; Pennisi et al., 2004; Bresciani et al., 2010; Coelho et al., 2010, 2011b; 
Vides et al., 2011; Sobrinho et al., 2012; Metzdorf et al., 2017; Berenguer et al., 2020; 
Fernandez-Gallego et al., 2020; Silva et al., 2020), bone marrow (Pennisi et al., 2004; Marcos et 
al., 2009; Vides et al., 2011; Sobrinho et al., 2012; Metzdorf et al., 2017; Marcondes et al., 2018; 
Fernandez-Gallego et al., 2020), liver (Vides et al., 2011Mohebali et al., 2017; Fernandez-
Gallego et al., 2020), spleen (Vides et al., 2011; Mohebali et al., 2017; Fernandez-Gallego et al., 
2020), nasal exudate (Migliazzo et al., 2015), corneal impression (Pimenta et al., 2015), and 
inflammatory breast fluid (Pereira et al., 2019c). Cytologic preparations consistent with FeL 
typically have a cell composition characteristic of pyogranulomatous, granulomatous or 
lymphoplasmacytic inflammation (Poli et al., 2002; Headley et al., 2019; Pereira et al., 2019c). 
Similar patterns are reported in histological studies on feline paraffin-embedded specimens (Poli 
et al., 2002; Navarro et al., 2010; Migliazzo et al., 2015; Di Mattia et al., 2018; Leal et al., 2018; 
Altuzarra et al., 2020). Nevertheless, compared with cytology, histology has the main advantage 
of providing a more detailed diagnostic information on the tissue architecture, which allows 
understanding if parasites are indeed associated with lesions (Paltrinieri et al., 2016). 
Immunohistochemistry may be further performed to confirm the presence of Leishmania 
organisms in biological samples obtained from cats (Poli et al., 2002; Navarro et al., 2010; 








been observed that this parasite may invade several feline organs/tissues such as skin (Ozon et 
al., 1998; Poli et al., 2002; Grevot et al., 2005; Rüfenacht et al., 2005; Attipa et al., 2017a; Rivas 
et al., 2018; Fernandez-Gallego et al., 2020; Silva et al., 2020), nasal and oral mucosa (Pennisi et 
al., 2004; Migliazzo et al., 2015; Leal et al., 2018), eyes (Hervás et al., 2001; Fernandez-Gallego 
et al., 2020), nasopharynx (Leal et al., 2018), stomach (Hervás et al., 1999), liver (Hervás et al., 
1999; Silva et al., 2020), kidneys (Ozon et al., 1998), spleen (Hervás et al., 1999; Grevot et al., 
2005; Marcos et al., 2009; Maia et al., 2015b; Fernandez-Gallego et al., 2020; Silva et al., 2020), 
bone marrow (Ozon et al., 1998; Pimenta et al., 2015; Silva et al., 2020), and lymph nodes 
(Hervás et al., 1999), and may also be associated with neoplasia (Grevot et al., 2005; Rüfenacht 
et al., 2005; Pocholle et al., 2012; Maia et al., 2015b; Altuzarra et al., 2020). 
Parasite culture is an accurate test allowing conclusive diagnosis of active infection. 
However, this test is not suitable for rapid diagnosis and is restricted to specialised laboratories. 
Parasite culture is a starting point for parasite identification and characterisation by isoenzyme 
electrophoresis (Pratlong et al., 2004). Viable parasites have been isolated from whole blood 
(Pocholle et al., 2012), nodular lesions (Poli et al., 2002; Basso et al., 2016), liver (Maia et al., 
2015b; Silva et al., 2020), spleen (Maia et al., 2015b; Silva et al., 2020), lymph nodes (Pennisi et 
al., 2004; Maroli et al., 2007; Maia et al., 2015b; Basso et al., 2016; Silva et al., 2020), and bone 
marrow (Silva et al., 2020) of cats with leishmaniosis. 
Polymerase chain reaction (PCR)-based tests has been allowed the identification of 
Leishmania DNA in several feline samples, including whole blood (Marcos et al., 2009; 
Pocholle et al., 2012; Pimenta et al., 2015; Basso et al., 2016; Attipa et al., 2017a; Brianti et al., 
2019; Fernandez-Gallego et al., 2020; Silva et al., 2020), buffy coat (Pereira et al., 2019c), 
conjunctival and oral swabs (Migliazzo et al., 2015Brianti et al., 2019; da Costa-Val et al., 
2020), hair (Urbani et al., 2020), skin (Rüfenacht et al., 2005; da Silva et al., 2010; Richter et al., 
2014; Maia et al., 2015b; Basso et al., 2016; Fernandez-Gallego et al., 2020; Silva et al., 2020), 
nasal tissue (Leal et al., 2018), liver (Maia et al., 2015b; Silva et al., 2020), spleen (Savani et al., 
2004; Coelho et al., 2010; da Silva et al., 2010; Maia et al., 2015b; Pimenta et al., 2015; 
Fernandez-Gallego et al., 2020; Silva et al., 2020), kidneys (da Silva et al., 2010), lymph nodes 
(Poli et al., 2002; Pennisi et al., 2004; Coelho et al., 2010; da Silva et al., 2010; Maia et al., 
2015b; Migliazzo et al., 2015; Pimenta et al., 2015; Silva et al., 2020), bone marrow (da Silva et 
al., 2010; Richter et al., 2014; Pimenta et al., 2015; Fernandez-Gallego et al., 2020; Silva et al., 
2020), and inflammatory breast fluid (Pereira et al., 2019c). Conventional PCR, nested PCR, and 
real-time PCR (qPCR) targeting kinetoplast minicircle DNA (kDNA) or the small subunit 
ribosomal DNA (SSU rDNA) multicopy genes have been widely used in routine veterinary 








as in epidemiological studies concerning Leishmania infection in cats (Maia et al., 2014; Vilhena 
et al., 2013; Pereira et al., 2020). Nevertheless, two-step PCR to amplify stretches of multicopy 
genes has increased sensitivity and should be preferred for suboptimal sample testing (i.e. where 
the parasite load tends to be low) such as whole blood (Pereira et al., 2020). On the other hand, 
quantitative PCR (qPCR) may further provide information about the amount of parasite DNA 
present in the sample (Galluzzi et al., 2018). This aspect is particularly relevant for monitoring 
the efficacy of anti-Leishmania treatments (Pocholle et al., 2012; Basso et al., 2016). However, it 
is important to highlight that a PCR-positive result may only reflect a transient infection and, for 
this reason, should be carefully interpreted in a clinical context. PCR products may be followed 
by restriction enzyme digestion (i.e. restriction fragment length polymorphism) and/or 
sequencing for parasite species identification (Metzdorf et al., 2017; Pereira et al., 2020).  
The most common serological tests used to detect anti-Leishmania antibodies in cats are 
based on enzyme-linked immunosorbent assay (ELISA) and immunofluorescent antibody test 
(IFAT). The latter is considered as the reference test for the serodiagnosis of canine and human 
leishmaniosis (OIE, 2018; WHO, 2010). Persichetti et al. (2017) established 1:80 serum dilution 
as IFAT cut-off for FeL serodiagnosis, and demonstrated that this test helps to detect subclinical 
or early Leishmania infections in cats. More recently, Iatta et al. (2020) validated IFAT as an 
accurate test to assess the exposure of cats to L. infantum, reporting positive and negative 
predictive values of 80.7% and 89.9%, respectively. Compared to IFAT, ELISA (cut-off 40 
ELISA units) presents a better performance for the serodiagnosis of clinical FeL (Persichetti et 
al., 2017). Western blot analysis is mainly intended for research but rarely available in routine 
practice. However, this test seems to offer the best diagnostic performance (considering an 18 
kDa band as a marker for positivity) to detect antibodies against L. infantum in cats (Persichetti 
et al., 2017). Direct agglutination test has also occasionally been used in both clinical and 
epidemiological contexts for serological diagnosis of FeL (Pimenta et al., 2015; Asgari et al., 
2020). Some authors have considered a cut-off value of 1:100 to distinguish infected from 
uninfected cats (Kongkaew et al., 2007; Cardoso et al., 2010; Maia et al., 2015a; Lopes et al., 
2017; Asgari et al., 2020; Neves et al., 2020). Indirect hemagglutination was exclusively 
performed in epidemiological studies in domestic cats in Egypt (Michael et al., 1982; Morsy et 
al., 1988; Morsy & Abou el Seoud, 1994).  
Cats with clinical leishmaniosis tend to present high antibody levels (Richter et al., 2014; 
Maia et al., 2015b; Pimenta et al., 2015; Basso et al., 2016), and specific treatment frequently 
leads to the reduction of anti-Leishmania antibodies (Pennisi et al., 2004; Richter et al., 2014; 
Basso et al., 2016; Pereira et al., 2019c). In some cases, an increase of antibody titres was 








serological result formally only reflects exposure to pathogens and should be interpreted in a 
clinical context (Paltrinieri et al., 2016).  
In conclusion, the diagnosis of FeL can be a real challenge for veterinarians and is 
seldom considered during the differential diagnosis. Therefore, the algorithm illustrated in Fig. 3 
is proposed for clinically healthy cats used as blood donors or for breeding purposes, and for cats 
with suspected leishmaniosis. 
 
7. Treatment and prognosis 
 
Treatment should be considered only after confirmation of disease (see Section 6). 
Although several treatment regimens have been empirically used for FeL (Table 6), no 
controlled studies about their efficacy and safety have been performed. Long-term administration 
of allopurinol as monotherapy is the most common regimen prescribed for FeL (Pennisi et al., 
2004; Leiva et al., 2005; Rüfenacht et al., 2005; Marcos et al., 2009; Pocholle et al., 2012; 
Richter et al., 2014; Maia et al., 2015b; Migliazzo et al., 2015; Pimenta et al., 2015; Basso et al., 
2016; Attipa et al., 2017a; Leal et al., 2018; Brianti et al., 2019; Pereira et al., 2019c; Altuzarra et 
al., 2020; Fernandez-Gallego et al., 2020). This drug is generally well-tolerated, but possible 
cases of cutaneous adverse reactions (Leal et al., 2018; Brianti et al., 2019), coprostasis (Maia et 
al., 2015b), and elevated liver enzymes (Rüfenacht et al., 2005) have been sporadically reported. 
Favourable results (i.e. clinical cure or improvement of clinical status) with allopurinol as 
monotherapy have been commonly obtained (Pennisi et al., 2004; Leiva et al., 2005; Rüfenacht 
et al., 2005; Pocholle et al., 2012; Richter et al., 2014; Migliazzo et al., 2015; Pimenta et al., 
2015; Attipa et al., 2017a; Fernandez-Gallego et al., 2020; Altuzarra et al., 2020). Nevertheless, 
relapse after discontinuation or low-dose administration (Pennisi et al., 2004; Leiva et al., 2005; 
Brianti et al., 2019; Pereira et al., 2019c) and no or poor response to allopurinol therapy have 
been occasionally reported, even in cats with no apparent history of concomitant infections or 
immunosuppressive therapies (Rüfenacht et al., 2005; Marcos et al., 2009; Basso et al., 2016; 
Fernandez-Gallego et al., 2020). Therefore, the combination of meglumine antimoniate and 
allopurinol has been proposed for FeL treatment, appearing to be more effective (Basso et al., 
2016; Pereira et al., 2019c), but acute kidney injury has already been reported (Leal et al., 2018). 
Although controversial, this drug is suspected of inducing nephrotoxicity in dogs (reviewed by 
Roura et al., 2021). Thus, its use in cats with altered renal function should be carefully 
considered. Meglumine antimoniate plus ketoconazole was used in a cat with cutaneous and 
systemic signs of FeL, resulting in apparent clinical cure (Hervás et al., 1999). Miltefosine was 








clinical improvement (Leal et al., 2018). In this case, transient vomiting episodes were reported 
in the first week of treatment with miltefosine but were managed using antiemetics (i.e. 
maropitant). Nevertheless, Fernandez-Gallego et al. (2020) recently reported a case of FeL with 
concomitant FIV infection not responsive to miltefosine plus allopurinol (combination therapy). 
Pennisi et al. (2004) reported treatment failure in a seropositive cat for FIV, T. gondii and B. 
henselae suffering from leishmaniosis. In this case, three distinct regimens were used (i.e. 
metronidazole plus spiramycin, fluconazole and itraconazole) (Pennisi et al., 2004). In another 
cat with leishmaniosis associated with an invasive squamous cell carcinoma, domperidone was 
used after unsuccessful allopurinol monotherapy, but clinical signs remained after one month of 
treatment (Maia et al., 2015b). The dietary supplement active hexose correlated compound 
(AHCC) was recently suggested as a possible alternative maintenance therapy to allopurinol 
(Leal et al., 2018). Surgical removal of lesions was also reported as an additional therapeutic 
approach (Hervás et al., 2001; Rüfenacht et al., 2005; Basso et al., 2016).  
Like in dogs, Leishmania parasites may persist in treated cats (Pocholle et al., 2012; 
Pimenta et al., 2015; Attipa et al., 2017a), suggesting that treatment may lead to clinical cure but 
may not eliminate the infection. 
Overall, FeL has a good prognosis even in cases with underlying viral infections (i.e. FIV 
or FeLV) (Hervás et al., 1999; Pennisi et al., 2004; Rüfenacht et al., 2005; Richter et al., 2014; 
Migliazzo et al., 2015; Pimenta et al., 2015; Basso et al., 2016; Attipa et al., 2017a; Leal et al., 
2018; Pereira et al., 2019c; Altuzarra et al., 2020; Fernandez-Gallego et al., 2020). On the other 
hand, panleukopaenia, acute kidney injury and lack of treatment seem to be critical factors 
associated with poor prognosis (Ozon et al., 1998; Hervás et al., 1999; Poli et al., 2002; Pennisi 
et al., 2004; Pimenta et al., 2015; Fernandez-Gallego et al., 2020). 
 
8. Prophylaxis and control 
 
No vaccines or drugs preventing leishmaniosis are currently available for use in cats, and 
most repellents avoiding infection in dogs are toxic to these felids. In endemic areas, cats are 
frequently exposed to phlebotomine sand fly bites, and this is associated with an increased risk 
of Leishmania infection (Pereira et al., 2019b). Chemoprophylaxis may be achieved by using a 
matrix collar containing 10% imidacloprid and 4.5% flumethrin. This formulation showed to be 
safe and effective in reducing infection risk by L. infantum in cats (Brianti et al., 2017). 
Nevertheless, keeping cats indoors during the period of vector activity (April to November in 
Mediterranean areas, see Alten et al., 2016) from dusk to dawn, as well as using physical barriers 
such as nets (i.e. mesh size 1,240 holes/in
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eschew exposure to phlebotomine sand fly bites, thereby minimising the risk of Leishmania 
infection. Spraying with residual insecticides on walls and roofs of human houses and animal 
shelters has been proposed as an additional measure for preventing CanL (Maroli et al., 2010). 
However, their use in environments with cats should be carefully considered since most of these 
products contain compounds (i.e. pyrethrins or pyrethroids) that can induce feline toxicosis. 
Isoxazolines, namely afoxolaner and fluralaner, have been regarded as a new promising class of 
drugs for controlling CanL and human leishmaniosis in endemic areas (Miglianico et al., 2018; 
Bongiorno et al., 2020; Queiroga et al., 2020). A spot-on formulation of fluralaner (112.5–500 
mg) is licensed for ectoparasite (i.e. ticks, fleas and mites) control in cats. This systemic 
insecticide induced long-term mortality of Lutzomyia longipalpis and Phlebotomus perniciosus 
(vectors of L. infantum in the New and Old Worlds, respectively) after feeding on treated dogs 
(Bongiorno et al., 2020; Queiroga et al., 2020). Similar results are expected to be observed in 
cats. Although studies are undoubtedly needed, this drug may also hypothetically represent an 
affordable indirect method for reducing Leishmania infection in cats in endemic areas. The 
detection and treatment of cats with leishmaniosis is also likely a beneficial control measure, as 
they may serve as a source of infection to phlebotomine sand fly vectors (Maroli et al., 2007; da 
Silva et al., 2010; Mendonça et al., 2020). In the absence of evidence indicating otherwise, 
Leishmania-infected cats should not be used for breeding or as blood donors due to the potential 
risk of transmission through blood transfusion and venereal/congenital infection, as reported in 
dogs (Owens et al., 2001; Naucke & Lorentz, 2012).  
In summary, and according to the current knowledge, the following prophylactic 
measures are proposed to prevent and control feline infection:  
 In endemic areas, keeping cats indoors from dusk to dawn during the phlebotomine sand 
fly season should be encouraged.  
 Use of physical barriers on houses and animal shelters located in endemic areas with high 
vector density. 
 Use of a matrix collar containing 10% imidacloprid and 4.5% flumethrin as well topical 
solutions containing 112.5–500 mg of fluralaner in cats living in or travelling to (cover 
the time of travel) endemic areas during the known transmission season. 
 After the return from endemic areas, cats should be clinically evaluated and tested. 
 Cats eligible for breeding and blood transfusion should be periodically tested.  
 Infected cats should not be used for breeding or as blood donors. 
 Cats with leishmaniosis should be treated and periodically monitored. 
 









Zoonotic visceral leishmaniosis (ZVL) caused by L. infantum is a life-threatening human 
disease endemic in the Mediterranean Basin, the Middle East, western Asia, and Brazil (WHO, 
2010). Domestic dogs are considered the primary source of human infection, which typically 
occurs via the bites of female phlebotomine sand flies (WHO, 2010). Nevertheless, during the 
last years, cats have been deserved attention due to their potential enrolment in ZVL 
epidemiology, appearing now as possible primary or secondary reservoir hosts (Asfaram et al., 
2019). This hypothesis arises by the following reasons (Maroli et al., 2007; da Silva et al., 2010; 
GfK, 2016; Pereira et al., 2019b, 2019c, 2020; Carneiro et al., 2020; Fernandez-Gallego et al., 
2020; Mendonça et al., 2020): 
 Cats are frequently exposed to the bites of competent vectors. 
 Cats are naturally susceptible to L. infantum infection. 
 Feline infection often runs a subclinical course. 
 Parasites are frequently found in the skin and blood of infected cats. 
 Naturally infected cats are infectious to competent vectors. 
 Naturally infected cats may be the source of infection to other mammals through 
competent vectors.  
 Strains of feline origin seem to be indistinguishable from those isolated from dogs, 
humans, and competent vectors. 
 Cats are among the most popular animals owned as a pet. 




During the last years, several studies concerning Leishmania infection in cats were 
conducted. Feline leishmaniosis has also gained importance appearing nowadays as an emergent 
disease. Nevertheless, its immunopathogenesis is poorly known. This protozoonosis is 
manifested by a broad spectrum of clinical signs and clinicopathological abnormalities, which, 
associated with the lack of standardised protocols, make its diagnosis further challenging for 
veterinarians. In this review, a diagnostic algorithm for FeL is proposed for clinical decision 
support. Treatment options currently available are empirical and suboptimal. The main form to 
prevent disease is to avoid infection. However, in contrast to dogs, very limited options are 
currently available to keep infective sand flies away from cats. Thus, a set of prevention 
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Legends to figures 
Fig. 1 Flow diagram of study searching and selection process 
 
Fig. 2 Worldwide distribution of Leishmania infection in cats (Felis spp.) 
 
Fig. 3 Proposed diagnostic algorithm for clinically healthy cats used as blood donors or for 









Epidemiological studies on the frequency of Leishmania infection in cats (Felis spp.) in the Old World 
Country Study Sampling 
year 
Species (origin) No. 
tested 
Method (test, cut-off/target 
gene) 
Sample % Positive (species)
a
 
Albania Silaghi et al. (2014) 2008–2010 F. catus (stray) 146 Serological (IFAT, 1:64) Serum 0.7 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 0 
Angola Lopes et al. (2017) 2014–2016 F. catus (domestic) 102 Serological (DAT, 1:100) Serum 0 
Bosnia and 
Herzegovina 
Colella et al. (2019) 2017 F. catus (domestic) 5 Serological (IFAT) Serum 0 
     Molecular (qPCR, kDNA) Whole blood 20.0 (Leishmania spp.) 
    1
b
 Molecular (PCR, kDNA) Whole blood 100 (L. infantum) 
     Molecular (qPCR, ITS2) Whole blood 100 (L. infantum) 
Cyprus Attipa et al. (2017) 2014 F. catus (domestic/shelter) 164 Serological (ELISA, 32 EU) Serum 4.4 (L. infantum) 
    174 Molecular (qPCR, kDNA) Whole blood 2.3 (L. infantum) 
Egypt Michael et al. (1982) na F. catus (stray) 80 Serological (IHA) Serum 3.8 (Leishmania spp.) 
 Morsy et al. (1988) na F. catus (stray) 28 Serological (IHA) Serum 3.6 (Leishmania spp.) 
 Morsy & Abou el Seoud 
(1994) 
na F. catus (domestic/stray) 60 Serological (IHA, 1:32) Serum 10.0 (Leishmania spp.) 
Germany Schäfer et al. (2021) 2012–2020 F. catus (domestic) 624 Serological (IFAT, 1:64) Serum 4.0 (Leishmania spp.) 
Greece Chatzis et al. (2014b, 2014a) 2009–2011 F. catus (domestic) 100 Parasitological (cytology) Bone marrow 0 
      Lymph node 0 
      Skin 0 
     Serological (ELISA, 0.145) Serum 1.0 (Leishmania spp.) 
     Serological (IFAT, 1:10) Serum 10.0 (Leishmania spp.) 
     Molecular (PCR, kDNA) Bone marrow 16.0 (L. infantum) 
      Whole blood 13.0 (L. infantum) 
    99 Molecular (PCR, kDNA) Skin 13.1 (L. infantum) 
    96  Conjunctival swab 3.1 (L. infantum) 
 Diakou et al. (2017) 2015 F. catus (stray) 148 Serological (IFAT, 1:80) Serum 6.1 (L. infantum) 
     Molecular (nPCR, SSU) Whole blood 6.1 (L. infantum) 
 Diakou et al. (2009) na F. catus (stray) 284 Serological (ELISA)  Serum 3.9 (Leishmania spp.) 
 Morelli et al. (2020) na F. catus 153 Serological (IFAT, 1:80) Serum 2.0 (L. infantum) 
Iran Mohebali et al. (2017) 2013–2015 F. catus (stray) 103 Serological (DAT, 1:320) Serum 3.9 (L. infantum) 
    4
b
 Parasitological (cytology) Liver 25.0 (L. infantum) 
      Spleen 25.0 (L. infantum) 
    4
b








      Spleen 0 
    1
b
 Molecular (nPCR, ITS2) Liver 100 (L. infantum) 
      Spleen 100 (L. infantum) 
 Akhtardanesh et al. (2020) 2016 F. catus (stray) 180 Molecular (nPCR, kDNA) Whole blood 13.9 (L. infantum) 
 Asgari et al. (2020) 2016–2018 F. catus (stray) 174 Serological (DAT, 1:100) Serum 17.2 (L. infantum) 
     Serological (ELISA) Serum 27.6 (L. infantum) 
     Molecular (nPCR, kDNA) Buffy coat 20.7 (L. infantum) 
 Sarkari et al. (2009) na F. catus (stray) 40 Serological (DAT, 1:20) Serum 20.0 (L. infantum) 
     Serological (IFAT, 1:10) Serum 25.0 (L. infantum) 
 Hatam et al. (2010) na F. catus (stray) 40 Parasitological (cytology) Liver 2.5 (Leishmania spp.) 
      Spleen 2.5 (Leishmania spp.) 
     Parasitological (culture) Liver 7.5 (Leishmania spp.) 
      Spleen 2.5 (Leishmania spp.) 
     Molecular (PCR, kDNA Liver 7.5 (L. infantum) 
      Spleen 5.0 (L. infantum) 
 Fatollahzadeh et al. (2016) na F. catus (stray) 65 Parasitological (cytology) Liver 0 
      Spleen 0 
     Parasitological (culture) Liver 0 
      Spleen 0 
     Serological (DAT, 1:320) Serum 23.1 (L. infantum) 
     Molecular (PCR, kDNA) Spleen 0 
 Akhtardanesh et al. (2017) na F. catus (stray) 60 Serological (ELISA) Serum 6.7 (L. infantum) 
     Molecular (nPCR, 7SL 
RNA) 
Whole blood 16.7 (L. infantum) 
       1.7 (L. tropica) 
Iraq Otranto et al. (2019) 2008 F. catus (stray) 207 Molecular (qPCR, kDNA) Whole blood 0 
Israel Nasereddin et al. (2008) 1999–2000 F. catus (domestic/stray) 104 Serological (ELISA) Serum 6.7 (L. infantum) 
 Baneth et al. (2020) 2018 F. catus (shelter) 67 Serological (ELISA, 0.4) Serum 75.0 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 16.0 (L. infantum) 
     Molecular (HRMPCR, ITS1) Whole blood 0 
Italy Vita et al. (2005) 2002–2004 F. catus (domestic/stray) 203 Serological (IFAT, 1:40) Serum 16.3 (L. infantum) 
    11
b
 Molecular (PCR) Lymph node 100 (L. infantum) 
      Whole blood 45.5 (L. infantum) 
 Spada et al. (2013) 2008–2010 F. catus (stray) 233 Serological (IFAT, 1:40) Serum 25.3 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 0 
 Morganti et al. (2019) 2010–2016 F. catus (shelter/stray) 286 Serological (IFAT, 1:40) Serum 9.1 (L. infantum) 
     Molecular (nPCR, SSU) Buffy coat 0 
      Conjunctival swab 15.7 (L. infantum) 
 Dedola et al. (2018) 2011–2013 F. catus (domestic) 90 Serological (IFAT, 1:40)  Serum 10.0 (L. infantum) 
     Molecular (nPCR, ITS) Whole blood 5.5 (L. infantum) 
 Veronesi et al. (2016) 2011–2014 F. silvestris (wild) 21 Molecular (qPCR, COII) Spleen 0 








     Molecular (qPCR, kDNA) Whole blood 42.8 (L. infantum) 
 Persichetti et al. (2018) 2012–2013 F. catus (domestic) 197 Parasitological (cytology) Whole blood 0 
     Serological (IFAT, 1:80) Serum 9.6 (L. infantum) 
     Molecular (qPCR, kDNA) Conjunctival swab 1.5 (L. infantum) 
    181 Molecular (qPCR, kDNA) Lymph node 1.7 (L. infantum) 
    143 Molecular (qPCR, kDNA) Urine 2.1 (L. infantum) 
    197 Molecular (qPCR, kDNA) Oral swab 1.5 (L. infantum) 
      Whole blood 2.0 (L. infantum) 
 Spada et al. (2016) 2014 F. catus (stray) 90 Serological (IFAT, 1:40) Serum 30.0 (L. infantum) 
     Molecular (qPCR, kDNA) Conjunctival swab 0 
      Lymph node 1.1 (L. infantum) 
      Whole blood 1.1 (L. infantum) 
 Brianti et al. (2017) 2015 F. catus (domestic) 159 Serological (IFAT, 1:80) Serum 9.4 (L. infantum) 
     Molecular (qPCR, kDNA) Conjunctival swab 3.8 (L. infantum) 
      Whole blood 7.5 (L. infantum) 
 Otranto et al. (2017) 2015–2016 F. catus (domestic) 330 Serological (IFAT, 1:40) Serum 25.7 (L. infantum) 
     Molecular (qPCR, kDNA) Conjunctival swab 1.8 (L. infantum) 
      Whole blood 2.1 (L. infantum) 
 Abbate et al. (2019) 2015–2017 F. silvestris (wild) 11 Molecular (qPCR, kDNA) Lymph 
node/skin/spleen 
0 
 Priolo et al. (2019) 2016–2017 F. catus (domestic/stray) 66 Serological (ELISA) Serum 17.0 (L. infantum) 
     Serological (IFAT, 1:80) Serum 14.0 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 4.0 (L. infantum) 
 Spada et al. (2020) 2016–2018 F. catus (stray) 102 Serology (IFAT, 1:80) Serum 4.9 (L. infantum) 
    117 Molecular (qPCR, kDNA) Conjunctival swab 0 
    115 Molecular (qPCR, kDNA) Lymph node 4.3 (L. infantum) 
    109 Molecular (qPCR, kDNA) Whole blood 0 
 Urbani et al. (2020) 2017 F. catus (domestic) 152 Serological (IFAT, 1:80) Serum 11.8 (L. infantum) 
    150 Molecular (qPCR, kDNA) Conjunctival swab 0 
      Hair 0.7 (L. infantum) 
    146 Molecular (qPCR, kDNA) Whole blood 0 
 Iatta et al. (2019) 2017–2018 F. catus (domestic) 2659 Serological (IFAT, 1:80) Serum 3.3 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 0.8 (L. infantum) 
 Ebani et al. (2020) 2018–2019 F. catus (stray) 85 Serological (IFAT) Serum 2.4 (Leishmania spp.) 
     Molecular (PCR, SSU)  Blood
c
 5.9 (Leishmania spp.) 
 Persichetti et al. (2017) 2013 na 76 Serological (ELISA, 40 EU) Serum 2.6 (L. infantum) 
     Serological (IFAT, 1:80) Serum 17.1 (L. infantum) 
     Serological (WB) Serum 18.4 (L. infantum) 
    21
b
 Serological (ELISA, 40 EU) Serum 100 (L. infantum) 
     Serological (IFAT, 1:80) Serum 95.2 (L. infantum) 
     Serological (WB) Serum 100 (L. infantum) 
 Poli et al. (2002) na F. catus (domestic) 110 Serological (IFAT, 1:80) Serum 0.9 (Leishmania spp.) 
 Morelli et al. (2019) na F. catus (domestic) 167 Serological (IFAT, 1:80) Serum 3.0 (L. infantum) 








Portugal Duarte et al. (2010) 2003–2005 F. catus (stray) 180 Serology (IFAT, 1:40) Serum 0.6 (L. infantum) 
 Maia et al. (2008) 2004 F. catus (stray) 20 Serological (IFAT, 1:64) Serum 0 
    23 Molecular (PCR, ITS1) Blood on filter paper 30.4 (Leishmania spp.) 
     Molecular (PCR, kDNA) Blood on filter paper 30.4 (Leishmania spp.) 
    4
b
 Molecular (PCR–RFLP, 
ITS1) 
Blood on filter paper 100 (L. infantum) 
 Cardoso et al. (2010) 2004–2008 F. catus (domestic) 316 Serological (DAT, 1:100) Serum 1.9 (L. infantum) 
     Serological (ELISA)  Serum 2.8 (L. infantum) 
 Maia et al. (2010) 2007–2008 F. catus (domestic/stray) 76 Serological (IFAT, 1:64) Serum 1.3 (Leishmania spp.) 
    138 Molecular (PCR, kDNA) Whole blood 20.3 (L. infantum) 
 Maia et al. (2015) 2011–2014 F. catus (domestic/stray) 271 Serological (DAT, 1:100) Serum 3.7 (L. infantum) 
 Maia et al. (2014) 2012–2013 F. catus (domestic/stray) 649 Molecular (nPCR, SSU) Whole blood 9.9 (Leishmania spp.) 
 Pereira et al. (2019a, b, 
2020) 
2017–2018 F. catus (domestic/ 
shelter/stray) 
373 Serological (IFAT, 1:64) Serum 1.6 (Leishmania spp.) 
    465 Molecular (nPCR, SSU) Buffy coat 5.4 (Leishmania spp.) 
    25
b
 Molecular (nPCR, cytB) Buffy coat 12.0 (L. donovani s.l.) 
       4.0 (L. major) 




     Molecular (PCR, g6pdh) Buffy coat 4.0 (L. donovani s.l.) 
     Molecular (nPCR, hsp70) Buffy coat 12.0 (L. donovani s.l.) 




     Molecular (nPCR, ITS) Buffy coat 12.0 (L. donovani s.l.) 
       4.0 (L. major) 
 Neves et al. (2020) 2018–2019 F. catus (domestic) 141 Serological (DAT, 1:100) Serum 0 
 Vilhena et al. (2013) na F. catus (domestic) 320 Molecular (qPCR, kDNA) Whole blood 0.3 (L. infantum) 
Portugal/Spain Mesa-Sanchez et al. (2020) 2015–2020 F. catus (domestic)
g
 173 Molecular (nPCR, SSU) Whole blood 0 
Qatar Lima et al. (2019) 2016–2018 F. catus (domestic/stray) 79 Molecular (qPCR, kDNA) Whole blood/on 
dried spot 
1.3 (Leishmania spp.) 
Saudi Arabia Morsy et al. (1999) na F. margarita (wild) 10 Parasitological (cytology) Liver 20.0 (Leishmania spp.) 
      Spleen 40.0 (Leishmania spp.) 
     Serological (IHA, 1:64) Serum 40.0 (Leishmania spp.) 
Spain Del Río et al. (2014) 2001–2006 Felis silvestris (wild)  4 Molecular (qPCR, kDNA) Liver and/or spleen 25.0 (L. infantum) 
    1
b
 Molecular (PCR, ITS2) Liver and/or spleen 100 (L. infantum) 
 Martín-Sánchez et al. (2007) 2003–2004 F. catus (domestic) 183 Serological (IFAT, 1:40) Serum 28.3 (Leishmania spp.) 
     Molecular (PCR-ELISA, 
kDNA) 
Whole blood 25.7 (L. infantum) 
    7
b
 Parasitological (culture) Leucoconcentrate 0 








 Ayllón et al. (2008) 2005–2006 F. catus (domestic) 233 Serological (IFAT, 1:100) Serum 1.3 (L. infantum) 
     Molecular (PCR, kDNA) Whole blood 0.4 (L. infantum) 
 Ayllón et al. (2012) 2005–2008 F. catus (domestic/stray) 680 Serological (IFAT, 1:50) Serum 3.7 (L. infantum) 
     Molecular (PCR, kDNA) Whole blood 0.6 (L. infantum) 
 Tabar et al. (2008) 2006 F. catus (domestic) 100 Molecular (qPCR, kDNA) Whole blood 3.0 (L. infantum) 
 Sherry et al. (2011) 2008 F. catus (shelter) 105 Serological (ELISA) Serum 13.2 (L. infantum) 
    104 Molecular (qPCR, kDNA) Whole blood 8.7 (L. infantum) 
 Millán et al. (2011) 2008–2009 F. catus (stray) 83 Serological (WB) Serum 15.7 (L. infantum) 
    73 Molecular (PCR, kDNA) Blood and/or spleen 25.6 (L. infantum) 
    14
b
 Molecular (PCR–RFLP, 
kDNA) 
Blood and/or spleen 100 (L. infantum) 
 Miró et al. (2014) 2012–2013 F. catus (stray) 346 Serological (IFAT, 1:100) Serum 3.2 (L. infantum) 
    57
d
 Molecular (nested PCR, 
ITS1) 
Whole blood 0 
     Molecular (nested PCR, 
SSU) 
Whole blood 0 
 Risueño et al. (2018) 2013–2015 F. silvestris (wild) 2 Molecular (qPCR, kDNA) Skin 50.0 (L. infantum) 
      Other organs
e
 0 
 Marenzoni et al. (2018) 2014–2015 F. catus (domestic) 31
g
 Molecular (PCR, kDNA) Whole blood 0 
 Montoya et al. (2018a) 2014–2017 F. catus (stray) 249 Serological (IFAT, 1:100) Serum 4.8 (L. infantum) 
     Molecular (PCR, ITS) Skin/whole blood 0 
 Priolo et al. (2019) 2016–2017 F. catus (domestic/stray) 113 Serological (ELISA) Serum 7.0 (L. infantum) 
     Serological (IFAT, 1:80) Serum 19.0 (L. infantum) 
     Molecular (qPCR, kDNA) Whole blood 5.0 (L. infantum) 
 Villanueva‐ Saz et al. 
(2021) 
2020 F. catus (stray) 114 Serological (ELISA, 13 EU) Serum 16.7 (L. infantum) 
 Solano-Gallego et al. (2007) na F. catus (domestic/stray) 445 Serological (ELISA-IgG, 53 
EU) 
Serum 5.3 (L. infantum) 
  na   Serological (ELISA-Prot A, 
44 EU) 
Serum 6.3 (L. infantum) 
 Alcover et al. (2020) na F. catus (wild) 1 Molecular (qPCR, kDNA) Liver 100 (Leishmania spp.) 
  na    Skin 100 (Leishmania spp.) 
  na    Spleen 100 (Leishmania spp.) 
 Miró et al. (2011) na F. catus (breeding) 20 Serological (IFAT, 1:100) Serum 15.0 (L. infantum) 
 Moreno et al. (2014) na F. catus (stray) 43 Serological (IFAT, 1:50) Serum 4.3 (L. infantum) 
 Montoya et al. (2018b) na F. catus (stray)  Serological (IFAT, 1:100) Serum 0 
Thailand Sukmee et al. (2008) 2006 F. catus 15 Serological (DAT; 1:100) Serum 60.0 (Leishmania spp.) 
    9
b
 Molecular (PCR, ITS1) Whole blood 0 
     Molecular (PCR, kDNA) Whole blood 0 
 Junsiri et al. (2017) 2013 F. catus (domestic) 250 Serological (ELISA, 0.2) Serum 5.6 (L. infantum) 
     Molecular (PCR, kDNA) Whole blood 0 
 Kongkaew et al. (2007) na F. catus 5 Serological (DAT, 1:100) Serum 20.0 (Leishmania spp.) 
    1
b








Turkey Dincer et al. (2015) 2013 F. catus (domestic/shelter) 22 Molecular (nPCR, kDNA) Whole blood 4.5 (L. infantum) 
 Karakuş et al. (2019) 2014 F. catus (stray) 5 Molecular (nPCR, SSU) Conjunctival swab 0 
  2015  8 Molecular (qPCR, ITS1) Conjunctival swab 12.5 (L. infantum) 
  2016  6 Molecular (qPCR, ITS1) Conjunctival swab 0 
 Dincer et al. (2016) 2015 F. catus (domestic/shelter) 50 Molecular (nPCR, kDNA) na 0 
 Dinçer et al. (2012) na F. catus (domestic) 1 Serological (IFAT) Serum 0 
     Molecular (PCR) na 0 
 Paşa et al. (2015) na F. catus (domestic) 147 Molecular (qPCR, ITS1) Whole blood 2.7 (L. major) 
       8.8 (L. tropica) 
     Molecular (qPCR, hsp70) Whole blood 2.0 (L. major) 
       2.7 (L. tropica) 
       2.7 (Leishmania spp.) 
 Can et al. (2016) na F. catus (shelter) 1101 Serological (ELISA) Serum 10.8 
     Serological (IFAT, 1:40) Serum 15.2 
     Molecular (qPCR, ITS1) Whole blood 0.1 (L. tropica) 
     Molecular (nPCR, kDNA) Whole blood 0.1 (L. infantum) 
       0.5 (L. tropica) 
UK Persichetti et al. (2017) 2013 F. catus 64 Serological (ELISA, 40 EU) Serum 1.6 (L. infantum) 
     Serological (IFAT, 1:80) Serum 0 
     Serological (WB) Serum 3.1 (L. infantum) 
Uzbekistan Kovalenko et al. (2011) na F. catus 1 Serological (ELISA) Serum 0 
a 
Species defined according to the original study. 
b 
Previously identified as positive by another test. 
c 
DNA extracted from the sediment obtained after centrifugation of the blood samples. 
d 






Cats eligible for blood donation. 
Abbreviations: COII, cytochrome oxidase II; cytB, cytochrome b; DAT, direct agglutination test; ELISA, enzyme-linked immunosorbent assay; EU, ELISA units; F., Felis; g6pdh, glucose-6-
phosphate dehydrogenase; HRMPCR, high resolution melt PCR; hsp70, heat-shock protein 70; IFAT, immunofluorescence antibody test; IgG, Immunoglobulin G; IHA, indirect 
hemagglutination; ITS, internal transcriber spacers; ITS1, internal transcriber spacer 1; ITS2, internal transcriber spacer 2; kDNA, kinetoplast minicircle DNA; L., Leishmania; na, not 
available; nPCR, nested PCR; PCR, one-step PCR (polymerase chain reaction); Prot A, Protein A; qPCR, real-time PCR; RFLP, restriction fragment length polymorphism; s.l., sensu lato; 









Epidemiological studies on the frequency of Leishmania infection in cats (Felis spp.) in the New World 
Country Study Sampling 
year 
Species (origin) No. 
tested 
Method (test, cut-off/target 
gene) 
Sample % Positive (species)
a
 
Brazil De Matos et al. (2018) 2004–2014 F. catus 679 Serological (ELISA) Serum 43.4 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 15.8 (Leishmania spp.) 
 Figueiredo et al. (2009) 2005 F. catus (domestic) 43 Serological (ELISA) Serum 2.4 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 0 
 Coelho et al. (2011a) 2007–2009 F. catus 70 Serological (ELISA) Serum 4.2 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 0.0 (Leishmania spp.) 
 Vides et al. (2011) 2008–2009 F. catus 55 Parasitological (cytology) Bone marrow  12.7 (Leishmania spp.) 
      Liver  3.6 (Leishmania spp.) 
      Lymph node 5.5 (Leishmania spp.) 
      Spleen 7.3 (Leishmania spp.) 
     Parasitological (IHC) Skin 16.4 (Leishmania spp.) 
     Serological (ELISA, 0.277) Serum 25.4 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 10.9 (Leishmania spp. 
    3 Molecular (qPCR, gp63) Whole blood 100 (L. chagasi) 
 Cardia et al. (2013) 2010 F. catus (shelter/stray) 386 Serological (IFAT, 1:40) Serum 0.5 (Leishmania spp.) 
 Silva et al. (2014) 2010 F. catus 
(domestic/shelter) 
153 Serological (ELISA) Serum 3.9 (L. infantum) 
 De Sousa Oliveira et al. 
(2015) 
2012 F. catus 52 Molecular (PCR, kDNA) Conjunctival swab 13.5 (Leishmania spp.) 
 de Sousa et al. (2014) 2013 F. catus (domestic/stray) 151 Serological (IFAT, 1:40) Serum 6.6 (L. infantum) 
 Metzdorf et al. (2017) 2013–2014 F. catus 
(domestic/shelter) 
100 Parasitological (cytology) Bone marrow  4.0 (Leishmania spp.) 
      Lymph node  4.0 (Leishmania spp.) 
      Whole blood 4.0 (Leishmania spp.) 
     Molecular (PCR-RFLP, 
kDNA) 
Bone marrow  6.0 (L. infantum) 
      Lymph node  3.0 (L. infantum) 
      Whole blood 4.0 (L. infantum) 
 Leonel et al. (2020) 2014 F. catus (shelter) 94 Serological (ELISA) Serum 31.9 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 29.8 (Leishmania spp.) 
     Molecular (PCR, kDNA) Conjunctival swab 0 
      Whole blood 0 




 Parasitological (cytology) Bone marrow 14.0 (Leishmania spp.) 
     Molecular (qPCR, kDNA) Bone marrow 86.0 (L. infantum) 
      Whole blood 72.0 (L. infantum) 
 Rocha et al. (2019) 2016–2017 F. catus (domestic) 105 Serological (IFAT, 1:40) Serum 30.5 (L. infantum) 
     Molecular (PCR, CH1)  Whole blood 2.9 (L. infantum) 








 Pedrassani et al. (2019) 2017 F. catus (domestic) 30 Serological (IFAT, 1:80) Serum 6.6 (L. infantum) 
     Molecular (PCR, kDNA) Whole blood 0 
 Berenguer et al. (2020) 2017 F. catus (domestic) 128 Molecular (PCR, kDNA) Conjunctival swab 0 
      Whole blood 0.8 (L. infantum) 
    3
c
 Parasitological (cytology) Lymph node 33.3 (Leishmania ssp.) 
     Molecular (PCR, kDNA) Lymph node 33.3 (L. infantum) 
 Bezerra et al. (2019) 2017–2018 F. catus (domestic) 91 Serological (IFAT, 1:40) Serum 15.4 (Leishmania spp.) 
     Molecular (PCR, kDNA) Whole blood 0 
 da Silva et al. (2008) na F. catus (domestic) 8 Serological (IFAT, 1:40) Serum 25.0 (Leishmania spp.) 
    3 Molecular (multiplex PCR, 
kDNA) 
Whole blood 66.7 (Leishmania spp.) 
    2
b
 Molecular (DB) Whole blood 100 (L. chagasi) 
 Bresciani et al. (2010) na F. catus (domestic) 283 Parasitological (cytology) Lymph node 0.7 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 0 
 Neto et al. (2011) na F. catus (shelter) 130 Serological (CAG-ELISA, 
0.449) 
Serum 23.0 (Leishmania spp.) 
     Serological (FML-ELISA, 
0.215) 
Serum 13.3 (Leishmania spp.) 
     Serological (rK39-ELISA, 
0.347) 
Serum 15.9 (Leishmania spp.) 
 Coelho et al. (2011b) na F. catus (domestic) 52 Parasitological (cytology) Bone marrow 0 
      Lymph node 3.8 (Leishmania spp.) 
      Spleen 0 
     Molecular (PCR, kDNA) Bone marrow 0 
      Lymph node 3.8 (L. chagasi) 
      Spleen 1.9 (L. chagasi) 
 Sobrinho et al. (2012) na F. catus (shelter/stray) 302 Parasitological (Cytology) Bone marrow 7.0 (Leishmania spp.) 
      Lymph node 7.9 (Leishmania spp.) 
     Serological (ELISA, 0.301) Serum 13.0 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 4.6 (Leishmania spp.) 
    5
b
 Molecular (qPCR, gp63) Whole blood 100 (L. infantum) 
 de Morais et al. (2013) na F. catus (domestic) 5 Molecular (qPCR, kDNA) Whole blood 80.0 (L. infantum) 
     Molecular (PCR, kDNA) Whole blood 80.0 (L. infantum) 
 Braga et al. (2014a) na F. catus (domestic) 50 Serological (IFAT, 1:40) Serum 4.0 (Leishmania spp.) 
 Braga et al. (2014b) na F. catus  100 Parasitological (culture) Whole blood 2.0 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 15.0 (Leishmania spp.) 
     Molecular, PCR, kDNA) Whole blood 0 
 Oliveira et al. (2015) na F. catus (domestic) 443 Serological (DAT, 1:40) Serum 5.6 (Leishmania spp.) 
     Serological (IFAT, 1:40) Serum 4.1 (Leishmania spp.) 
 Benassi et al. (2017) na F. catus (domestic/stray) 108 Molecular (PCR, kDNA) Conjunctival swab 1.9 (Leishmania spp.) 
      Whole blood 0 
     Molecular (qPCR, kDNA) Conjunctival swab 1.9 (Leishmania spp.) 
      Whole blood 0 
    2
b
 Molecular (PCR, ITS1) Conjunctival swab 50.0 (L. infantum) 








     Parasitological (culture) Bone marrow 0 
     Serological (IFAT, 1:40) Serum 54.0 (Leishmania spp.) 
    54
b
 Molecular (PCR, kDNA) Bone marrow/skin 0 
 da Costa-Val et al. (2020) na F. catus (domestic) 64 Serological (ELISA, 0.955) Serum 29.8 (Leishmania spp.)  
    64 Molecular (PCR, kDNA) Conjunctival swab 6.3 (Leishmania spp.) 
    64 Molecular (PCR, kDNA) Oral swab 4.7 (Leishmania spp.) 
    8
b
 Molecular (PCR-RFLP, 
ITS1) 
Conjunctival swab 12.5 (L. infantum) 
      Oral swab 37.5 (L. infantum) 
       12.5 (L. braziliensis) 
Honduras Mccown & Grzeszak, 2010) na F. catus (stray) 12 Serological (IFAT, 1:32) Serum 25.0 (L. donovani) 
Mexico Longoni et al. (2012) 2008–2009 F. catus (stray) 95 Serological (ELISA-H) Serum 5.3 (L. braziliensis) 
       13.7 (L. infantum) 
       1.1 (L. mexicana) 
     Serological (ELISA-SODe) Serum 11.6 (L. baziliensis) 
       22.1 (L. infantum) 
       10.5 (L. mexicana) 
     Serological (WB) Serum 10.5 (L. baziliensis) 
       20.0 (L. infantum) 
       10.5 (L. mexicana) 
Venezuela Viettri et al. (2018) na na 5 Molecular (nested-PCR, 
ITS1) 
Blood on filter paper 20.0 (Leishmania spp.) 
     Molecular (nPCR, SSU 
rDNA) 
Blood on filter paper 20.0 (Leishmania spp.) 
 Rivas et al. (2018)  F. catus (domestic/stray) 6 Parasitological (cytology) Skin lesions 66.7 (Leishmania spp.) 
    5 Parastiological (histology) Skin lesions 80.0 (Leishmania spp.) 
    5 Parasitological (IHC) Skin lesions 100 (Leishmania spp.) 
    30 Serological (ELISA, 15.3 
EU) 
Serum 6.7 (L. braziliensis) 
     Serological (ELISA, 15.3 
EU) 
Serum 6.7 (L. infantum) 
     Serological (WB) Serum 33.3 (L. braziliensis) 
     Serological (WB) Serum 33.3 (L. infantum) 
    31 Molecular (qPCR, kDNA) Whole blood 9.7 (Leishmania spp.) 
    5 Molecular (qPCR, kDNA) Skin lesions 100 (Leishmania spp.) 
     Molecular (qPCR, ITS1) Skin lesions 40.0 (L. mexicana) 
    2
b
 Molecular (PCR-RFLP, 
ITS1) 
Skin lesions 50.0 (L. mexicana) 
 Paniz Mondolfi et al. (2019) na na 12 Molecular (nPCR, cytB) Skin lesions 83.3 (L. mexicana) 
       16.7 (Leishmania spp.) 
a 
Species defined according to the original study. 
b 









 Cats with lymphadenomegaly. 
Abbreviations: CAG, crude antigen; CH1, chitinase; cytB, cytochrome b; DAT, direct agglutination test; DB, dot blot; ELISA, enzyme-linked immunosorbent assay; EU, ELISA units; F., 
Felis; FML, fucose-mannose ligand; gp63, metalloprotease gp63; H, total parasite extract; IFAT, immunofluorescence antibody test; IHC, immunohistochemistry; ITS1, internal transcriber 
spacer 1; kDNA, kinetoplast minicircle DNA; L., Leishmania; na, not available; nPCR, nested-PCR; PCR, one-step PCR (polymerase chain reaction); qPCR, real-time PCR; RFLP, restriction 









Frequency of clinical signs in domestic cats (Felis catus) with clinical leishmaniosis caused by Leishmania infantum 




Nodules 38 Poli et al. (2002); Savani et al. (2004); Rüfenacht et al. (2005); Richter et al. (2014); Pimenta et al. 
(2015); Basso et al. (2016); Attipa et al. (2017); Leal et al. (2018); Brianti et al. (2019); Headley et al. 
(2019); Pereira et al. (2019); Fernandez-Gallego et al. (2020); Silva et al. (2020) 
Erosive/ulcerative skin disease 37 Ozon et al. (1998); Hervás et al. (1999, 2001); Pennisi et al. (2004); Grevot et al. (2005); Rüfenacht et 
al. (2005); Coelho et al. (2010); Pocholle et al. (2012); Maia et al. (2015); Basso et al. (2016); Brianti 
et al. (2019); Headley et al. (2019); Fernandez-Gallego et al. (2020); Silva et al. (2020) 
Scaling/crusting 21 Ozon et al. (1998; Hervás et al. (1999); Pennisi et al. (2004); Rüfenacht et al. (2005); Coelho et al. 
(2010); da Silva et al. (2010); Headley et al. (2019); Fernandez-Gallego et al. (2020) 
Alopecia 12 Hervás et al. (1999); Pennisi et al. (2004); Rüfenacht et al. (2005); Fernandez-Gallego et al. (2020) 
Onychogryphosis 6 da Silva et al. (2010); Headley et al. (2019) 
Bloody cyst 4 Pennisi et al. (2004) 
Depigmentation 4 Rüfenacht et al. (2005); Pocholle et al. (2012) 
Pruritus 4 Rüfenacht et al. (2005); Pocholle et al. (2012) 
Pustule/papule 4 Rüfenacht et al. (2005); Pocholle et al. (2012) 
Footpad hyperkeratosis 2 Fernandez-Gallego et al. (2020) 
General/miscellaneous 
Lymphadenomegaly 27 Hervás et al. (1999, 2001); Poli et al. (2002); Pennisi et al. (2004); Savani et al. (2004); Maroli et al. 
(2007); da Silva et al. (2010); Brianti et al. (2019); Fernandez-Gallego et al. (2020); Silva et al. (2020) 
Lethargy/depression 25 Poli et al. (2002); Pennisi et al. (2004); Leiva et al. (2005); Rüfenacht et al. (2005); Marcos et al. 
(2009); Pocholle et al. (2012); Richter et al. (2014); Fernandez-Gallego et al. (2020) 
Anorexia/inappetence 21 Pennisi et al. (2004); Rüfenacht et al. (2005); Marcos et al. (2009); da Silva et al. (2010); Fernandez-
Gallego et al. (2020) 
Weight loss 21 Ozon et al. (1998); Hervás et al. (1999); Pennisi et al. (2004); Savani et al. (2004); da Silva et al. 
(2010); Fernandez-Gallego et al. (2020); Silva et al. (2020) 
Hyperthermia 12 Leiva et al. (2005); Basso et al. (2016); Headley et al. (2019); Fernandez-Gallego et al. (2020) 
Hepatomegaly 4 Pennisi et al. (2004); Leiva et al. (2005) 
Splenomegaly 4 Poli et al. (2002); Leal et al. (2018) 
Bruising 2 Maia et al. (2015) 
Mastitis 2 Pereira et al. (2019) 
Ocular 
Uveitis 27 Hervás et al. (2001); Pennisi et al. (2004); Verneuil (2013); Richter et al. (2014); Pimenta et al. 
(2015); Leal et al. (2018); Pereira et al. (2019); Fernandez-Gallego et al. (2020) 
Corneal oedema 10 Hervás et al. (2001); Pimenta et al. (2015); Fernandez-Gallego et al. (2020) 
Conjunctivitis 8 Migliazzo et al. (2015); Brianti et al. (2019); Fernandez-Gallego et al. (2020) 








Corneal opacification 4 Hervás et al. (2001); Pimenta et al. (2015) 
Glaucoma 4 Leiva et al. (2005); Richter et al. (2014) 
Keratitis 4 Richter et al. (2014); Fernandez-Gallego et al. (2020) 
Blepharitis 2 Brianti et al. (2019) 
Chemosis 2 Fernandez-Gallego et al. (2020) 
Masse 2 Hervás et al. (2001) 
Gastrointestinal/abdominal 
Stomatitis 21 Hervás et al. (2001); Leiva et al. (2005); Maroli et al. (2007); Verneuil (2013); Maia et al. (2015); 
Migliazzo et al. (2015); Fernandez-Gallego et al. (2020) 
Glossitis 4 Fernandez-Gallego et al. (2020) 
Jaundice 4 Hervás et al. (1999); Fernandez-Gallego et al. (2020) 
Vomiting 4 Hervás et al. (1999); Fernandez-Gallego et al. (2020) 
Abdominal distension 2 Leiva et al. (2005) 
Diarrhoea 2 Fernandez-Gallego et al. (2020) 
Cardiorespiratory 
Dispnoea/tachypnoea 12 da Silva et al. (2010); Basso et al. (2016); Leal et al. (2018); Headley et al. (2019); Silva et al. (2020) 
Pallor 10 Hervás et al. (2001); Pennisi et al. (2004); Marcos et al. (2009); Maia et al. (2015); Richter et al. 
(2014) 
Abnormal respiratory sounds 4 Leal et al. (2018); Altuzarra et al. (2020) 
Nasal discharge 4 Migliazzo et al. (2015); Altuzarra et al. (2020) 
Sneezing 2 Leal et al. (2018) 
Musculoskeletal 
Muscle atrophy 2 da Silva et al. (2010) 
Neurological 
Ataxia 2 Fernandez-Gallego et al. (2020) 
Urogenital 
Vaginal bleeding 2 Maia et al. (2015) 
a

















Anaemia 31 Hervás et al. (1999); Pennisi et al. (2004); Marcos et al. (2009); Richter et al. 
(2014); Pereira et al. (2019); Fernandez-Gallego et al. (2020); Pimenta et al. 
(2015)  
Neutrophilia 19 Poli et al. (2002); Leiva et al. (2005); da Silva et al. (2010); Verneuil (2013); 
Fernandez-Gallego et al. (2020); Silva et al. (2020) 
Thrombocytopaenia 17 Pennisi et al. (2004); Marcos et al. (2009); Richter et al. (2014); Pimenta et al. 
(2015); Basso et al. (2016); Pereira et al. (2019) 
Leukocytosis 10 Ozon et al. (1998); da Silva et al. (2010); Fernandez-Gallego et al. (2020) 
Leukopaenia 10 Pennisi et al. (2004); Rüfenacht et al. (2005); Richter et al. (2014) 
Eosinophilia 7 Ozon et al. (1998); Hervás et al. (1999); Marcos et al. (2009); Altuzarra et al. 
(2020) 
Neutropaenia 5 Fernandez-Gallego et al. (2020) 
Lymphopaenia 2 Rüfenacht et al. (2005) 
Monocytosis 2 Leiva et al. (2005) 
Blood chemistry 
Hyperproteinaemia 36 Ozon et al. (1998); Hervás et al. (1999); Poli et al. (2002); Pennisi et al. 
(2004); Pimenta et al. (2015); Attipa et al. (2017); Leal et al. (2018); Brianti 
et al. (2019); Pereira et al. (2019); Fernandez-Gallego et al. (2020)  
Hyperglobulinaemia 31 Pennisi et al. (2004); Leiva et al. (2005); Richter et al. (2014); Pimenta et al. 
(2015); Brianti et al. (2019); Altuzarra et al. (2020) 
Azotemia 21 Pennisi et al. (2004); Leiva et al. (2005); Marcos et al. (2009); da Silva et al. 
(2010); Leal et al. (2018); Fernandez-Gallego et al. (2020) 
Hypoalbuminaemia 10 Hervás et al. (1999; Rüfenacht et al. (2005); Richter et al. (2014); Fernandez-
Gallego et al. (2020)  
Hyperglycaemia 8 Leiva et al. (2005); Richter et al. (2014); Fernandez-Gallego et al. (2020) 
Bilirrubinaemia 5 Fernandez-Gallego et al. (2020) 
Hyperphosphataemia 3 Fernandez-Gallego et al. (2020) 
Hypophosphataemia 3 Fernandez-Gallego et al. (2020) 
Increased alanine 
aminotransferase 
3 Fernandez-Gallego et al. (2020) 
Increased aspartate 
transaminase 
3 da Silva et al. (2010) 
Increased creatinine kinase 3 Fernandez-Gallego et al. (2020) 
Protein electrophoresis 
Hypergammaglobulinaemia 84 Ozon et al. (1998); Hervás et al. (1999); Poli et al. (2002); Pennisi et al. 
(2004); Leiva et al. (2005); Marcos et al. (2009); Richter et al. (2014); Basso 
et al. (2016); Leal et al. (2018); Brianti et al. (2019); Pereira et al. (2019); 
Altuzarra et al. (2020); Fernandez-Gallego et al. (2020) 
Increased α2 globulins 13 Basso et al. (2016); Fernandez-Gallego et al. (2020) 
Hyperbetaglobulinaemia 3 Hervás et al. (1999) 
Urinalysis 
Proteinuria 25 Marcos et al. (2009); Leal et al. (2018); Fernandez-Gallego et al. (2020) 
Bilirrubinuria 4 Marcos et al. (2009) 
Glycosuria 4 Leiva et al. (2005) 
a









Common laboratory tests performed for diagnostic of Leishmania infection in domestic cats (Felis catus) 






Preferential sample Advantages Disadvantages Observations 
Parasitological  
Cytology Detection of 
parasites 
+++ + ‣  Bone-marrow (FNB); 
‣  Lymph node (FNB); 
‣  Nodular lesions (FNB); 
‣  Erosive/ ulcerative skin 
lesions (scraping) 
‣  Does not require specific 
laboratory equipment; 
‣  Low cost; 
‣  Rapid; 
‣  High specificity 
‣  Requires experienced 
observers;  
‣  Strictly qualitative; 
‣  Not suitable for identification 
at the species level 
‣  Amastigotes can 
be found in both 
intracellular and 
extracellular areas 
Histopathology Detection of 
parasites 
+++ + ‣  Skin/ocular lesions; 
‣  Bone marrow; 
‣  Lymph-nodes; 
‣  Spleen 
‣  Preserves structure and 
maintains tissue pathology; 
‣  High specificity; 
‣  Good sensitivity using 
IHC  
‣  Invasive; 
‣  Requires experienced 
observer;  
‣  Requires specific laboratory 
equipment; 
‣  More laborious and time-
consuming; 
‣  IHC is not widely available; 
‣  Only qualitative; 
‣  Not suitable for identification 
at the species level 
 
Parasite culture Isolation of 
viable 
parasites 
++ + ‣  Biopsy lesions; 
‣  Bone marrow; 
‣  Lymph nodes 
‣  Provides parasites for 
further analysis; 
‣  Confirms active infection; 
‣  High specificity 
‣  Labour-intensive; 
‣  Restricted to specialised 
reference laboratories; 
‣  Up to more than 30 days to 
provide a result; 
‣  Only qualitative; 
‣  Not suitable for identification 
at the species level 
‣  Aseptic sampling 
should be ensured; 
‣  Biopsy sample 
must be 
homogenised in 




PCR Detection of 
parasite DNA 
+++ +++ ‣  Biopsy lesions; 
‣  Bone marrow; 
‣  Lymph nodes 
‣  Allows identification at 
the species level; 
‣  High sensitivity and 
specificity 
‣  Transient infection cannot be 
excluded; 
‣  Requires specific laboratory 
equipment; 
‣  Requires vigilance against 
false-positive results; 
‣  Only qualitative; 
‣  Expensive 
 
















qPCR Detection of 
parasite DNA 
+++ +++ ‣  Biopsy lesions 
‣  Bone marrow 
‣  Lymph nodes 
‣  Allows identification at 
the species level; 
‣  High sensitivity and 
specificity; 
‣  Quantification of parasite 
load; 
‣  Reduced cross-
contamination probability; 
‣  Valuable for treatment 
follow-up; 
‣  Qualitative/quantitative 
‣  Transient infection cannot be 
excluded; 
‣  Standardised methods to 
parasite load quantification may 
not be offered by some 
laboratories; 
‣  Expensive 










+++ ++ ‣  Serum; 
‣  Plasma 
‣  Valuable for treatment 
follow-up; 
‣  Relatively low cost; 
‣  Qualitative/quantitative 
‣  Possible cross-reactivity; 
‣  Difficult to assess results at 
threshold of positivity; 
‣  Not suitable for unambiguous 
identification at the species level 
‣  Established cut-
off (40 EU) 
 
IFAT Detection of 
specific 
antibodies 
++ +++ ‣  Serum; 
‣  Plasma 
‣  Valuable for treatment 
follow-up; 
‣  Relatively low cost; 
‣  Qualitative/quantitative 
 
‣  Requires experienced 
observers;  
‣  Subjective interpretation; 
‣  Possible cross-reactivity; 
‣  Not suitable for unambiguous 
identification at the species level 
‣  Reference 
method for the 
serodiagnosis of 
human and canine 
leishmanioses; 
‣  Established cut-
off (1:80) 
Western blot Detection of 
specific 
antibodies 
+++ +++ ‣  Serum; 
‣  Plasma 
‣  High sensitivity and 
specificity 
‣  Labour-intensive; 
‣  Expensive; 
‣  Not available in routine 
practice; 
‣  Marker for 
positivity: 18 kDA 
band 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; EU, ELISA units; FNB, Fine needle biopsy; IFAT, immunofluorescence antibody test; IHC, immunohistochemistry, KDa, 









Treatment regimens used for feline leishmaniosis 




 Issues to consider Reference 
Monotherapy 
 Allopurinol (10–30 
mg/kg or 100 
mg/cat PO q12–
24h; for long-term) 
Variable (no 








Secondary xanthine urolithiasis has 
been reported in dogs 
Pennisi et al. (2004); Rüfenacht et al. (2005); Marcos 
et al. (2009); Pocholle et al. (2012); Richter et al. 
(2014); Maia et al. (2015); Migliazzo et al. (2015); 
Pimenta et al. (2015); Basso et al. (2016); Leal et al. 
(2018); Attipa et al. (2017); Brianti et al. (2019); 
Pereira et al. (2019); Altuzarra et al. (2020); 
Fernandez-Gallego et al. (2020) 
 Domperidone (0.5 
mg/kg PO q24h for 
1 month) 
No improvement Not reported Immunomodulatory drug used on 
prevention and treatment of CanL  
Maia et al. (2015) 
 Fluconazole (5 
mg/kg PO q24h for 
2 months) 
No response Not reported May be hepatotoxic Pennisi et al. (2004) 
 Itraconazole (50 
mg/cat PO q24h for 
2 months) 
No response Not reported Hepatotoxic drug; may lead to 
suppression of adrenal function 
Pennisi et al. (2004) 
 Meglumine 
antimoniate (50 
mg/kg SC q24h for 
25 days) 
Not applicable AKI - suspected Treatment stopped due to AKI 
development; painful to administer; 
may be nephrotoxic (controversial) 
Leal et al. (2018) 
 Meglumine 
antimoniate (300 








mg/kg SC q24h for 
30 days) plus 
allopurinol (10 










Proposed for FeL refractory cases Pimenta et al. (2015); Basso et al. (2016); Pereira et 
al. (2019); Fernandez-Gallego et al. (2020) 
 Meglumine 
antimoniate (5 
mg/kg SC q24h) 
Resolution of 
lesions 
Not reported; see 
meglumine 
antimoniate 
According to BSAVA (2020) 
ketoconazole is not recommended for 
cats 









(10 mg/kg q24h); 3 
cycles of 4 weeks, 
10 days apart 
monotherapy 
 Metronidazole (25 
mg/kg PO q24h for 
35 days) plus 
spiramycin 
(150,000 IU/kg PO 
q24h for 35 days) 
No response Not reported  Pennisi et al. (2004) 
 Miltefosine (2 
mg/kg PO q24h for 
28 days) plus N-
AHCC (½ tablet 








Miltefosine licenced formulations for 
CanL contain propylene glycol which 
can hypothetically induce Heinz body 
haemolytic anaemia in cats (Pennisi & 
Persichetti, 2018) 
Leal et al. (2018) 
 Miltefosine (2 
mg/kg PO q24h for 
28 days) plus 
allopurinol (10 
mg/kg PO q12 for 
long-term) 
No response See previous line See previous line Fernandez-Gallego et al. (2020) 
a 
Reported during treatment of cats with clinical leishmaniosis. 
b 
Associated with high doses (50 mg/kg q24h). 








● Original articles unrelated with Leishmania infection in
cats (Felis spp.) (n = 191)
● Review/comment/opinion articles/guidelines (n = 65)
● Article not available (n = 9)
● Erratum (n = 2)
● Case reports of feline leishmaniosis with ambiguous
identification of parasites at species level (n = 2)
● Epidemiological studies with ambiguous information
about cat’s (Felis spp.) geographical origin (n = 1)
● Feline experimental infection studies with complex species
other than Leishmania donovani sensu lato (n = 1)
● Original articles with ambiguous information about the
detection of Leishmania spp. in cats (Felis spp.) (n = 1)
● Unclear identification of host species (n = 1)
● Duplicate data (n = 1)






































Domestic cat (Felis catus)








Putative L. major/L. donovani hybrid
Leishmania DNA or anti-Leishmania












Are lymph node biopsies?
Clinically healthy cats
(living or travelling to endemic areas)
















With cutaneous, mucosal or
ocular lesions, or
lymphadenopathy















qPCR – Quantitative real-time polymerase
chain reaction
→ kinetoplast minicircle DNA
QST – Quantitative serology test
IHC – Immunohistochemistry
















 A comprehensive review on epidemiology, immunopathogenesis, diagnosis, treatment, and 
prevention of feline leishmaniosis. 
 An algorithm for assisting medical diagnosis of leishmaniosis in cats is suggested. 
 Guidelines for the prevention of Leishmania infection in cats are provided. 
 Dermatological lesions are the most common clinical manifestations. 
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